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Background: Recent studies suggest that coexistence of chronic obstructive pulmonary disease (COPD) might be
independently related to a worse prognosis for lung cancer. However, because data on the substantial prevalence
of COPD and its severity in Asian lung cancer patients remain limited, clinical impact of prevalence and severity of
COPD among the population has not been fully evaluated. Furthermore, patients with COPD often have
comorbidities. Thus, whether the decision-making process for therapeutic management of lung cancer patients
might be independently affected by COPD remains elusive.
Methods: Clinical impact of prevalence and severity of COPD were evaluated in 270 Japanese patients with newly
diagnosed lung cancer who were sequentially registered and underwent bronchoscopy from August 2010 to July
2012 at Nagoya University hospital. Furthermore, to explore whether or not the severity of airflow obstruction
might affect the decision to propose thoracic surgery with curative intent, we evaluated data from patients with
lung cancer at stage 1A to 3A who underwent spirometry and bronchoscopy.
Results: The prevalence rate of COPD was 54.4% among Japanese patients with lung cancer who underwent
bronchoscopy. The incidence of Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 1 and 2 was
significantly higher than that of GOLD grade 3. Although COPD-related comorbidities were not independent factors
for proposing thoracic surgery, the number of thoracic surgeries performed was significantly less in the COPD group
than the non-COPD group. Multivariate analysis showed that more severe airway obstruction, advanced clinical staging,
and higher age, were independent factors associated with the decision on thoracic surgery.
Conclusions: We demonstrated a high prevalence of COPD among Japanese lung cancer patients. Based on the
knowledge that severity of COPD is one of the most important factors in the therapeutic decision, comprehensive
assessment of COPD at bronchoscopy might allow us to implement the optimum management for lung cancer
patients.
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Chronic obstructive pulmonary disease (COPD) and
lung cancer are projected to continue to increase the
burden of disease worldwide until 2020 [1,2]. Many
studies suggest that COPD might be independently re-
lated to a worse prognosis for lung cancer [3-6]. A recent
review suggests more inclusive consideration for surgical
resection with curative intent in lung cancer patients
with COPD because limited surgical resections or non-
surgical therapeutic options might provide inferior sur-
vival compared with resection [6]. However, because
older patients with COPD are often known to have much
lower pulmonary function as well as other comorbidities
[7,8], whether or not the decision-making process for
therapeutic management of lung cancer patients might
be independently affected by the coexistence and severity
of COPD remains elusive. Recent studies show that the
prevalence of COPD is 40-70% of smokers diagnosed
with lung cancer [9,10]. On the other hand, many studies
suggest that the increasing incidence of adenocarcinoma
in Asian populations including the Japanese population
might be associated with epidermal growth factor recep-
tor (EGFR) mutation rather than with smoking [11,12].
Zhang, et al. show a low prevalence of COPD in hospital-
ized lung cancer patients in China (21.6%; 705/3263
cases) [13], whereas we recently demonstrated that the
prevalence of COPD was more than 40% in Japanese
patients undergoing thoracic surgery [14]. Because an-
other therapeutic option besides surgery, such as chemo-
therapy and/or radiation, might be selected for the older
lung cancer patients with COPD [8], substantial preva-
lence of COPD among Asian patients with newly diag-
nosed lung cancer might be higher than that in our study
[14]. Thus, data on the prevalence of COPD and its
severity in Asian populations remain limited. Taken
together, clinical impact of prevalence and severity of
COPD among Asian lung cancer patients should be
determined. Bronchoscopy is performed for most pa-
tients with lung cancer before the decision is made for
treatment of lung cancer. In the present study, the associ-
ation of COPD prevalence with lung cancer characteris-
tics was evaluated by spirometry among 270 Japanese
patients with lung cancer who underwent bronchoscopy.
We also evaluated whether or not the prevalence and se-
verity of COPD might independently affect the decision-




Patients with lung cancer who underwent bronchos-
copy at Nagoya University hospital from August 2010
to July 2012 were the subjects of this retrospective
study. The study was approved by the Institutional ReviewBoard of Nagoya University Graduate School of Medicine
(No 27-2) [14].
Information about patient characteristics, pathological
diagnosis of lung cancers, and clinical staging of lung
cancers, was obtained from hospital records as previ-
ously reported [14]. COPD-related systemic comorbidities
were defined as diabetes, hypertension, hyperlipidemia, or
ischemic cardiac disease [7]. Spirometry screening assess-
ment was performed on admission of the patients under-
going bronchoscopy. Spirometry was performed with a
calibrated dry spirometer, a FUDAC-77 (Fukuda Denshi
Co., Ltd., Tokyo, Japan), according to the American
Thoracic Society (ATS) standards applied in our hospital
[15]. Subjects were assigned to the COPD group, if they
had airflow obstruction as determined by an FEV1/FVC
ratio was below 0.70, and the remaining subjects were
assigned to the non-COPD group [9,10]. Reversibility, for
which an improvement of 200 ml in FEV1 and 12% in
FEV1 from baseline was defined as positive, was also
evaluated 15 minutes after a short-acting beta2-agonist
was given. Severity of airflow limitation in COPD was
determined by using the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) grade [16]; that is,
grade 1 (%FEV1 predicted >80%), grade 2 (50% <%FEV1
predicted <80%), grade 3 (30% <%FEV1 predicted <50%),
and grade 4 (%FEV1 predicted <30%). When the patients
did not undergo spirometry as a screening assessment at
a bronchoscopy, data were collected from the pre-
operative pulmonary assessment for those undergoing
thoracic surgery or from a spirometric assessment before
the bronchoscopy. Information about the existence of em-
physema from the chest computed tomography (CT) was
obtained from radiological reports. Clinical staging of lung
cancer was based on the tumor, node, metastasis (TNM)
staging using the standards of the Union International
Contre le Cancer (UICC), 7th edition [17]. Histological type
of adenocarcinoma, squamous cell carcinoma (Sq), large
cell carcinoma (Large), small cell lung carcinoma (SCLC),
and non-small cell lung carcinoma (NSCLC) was deter-
mined according to the World Health Organization’s clas-
sification [18]. We also collected information about the
status of EGFR mutation in lung cancers from patient
records.
Statistical analysis
All data were checked for completeness, and the ana-
lyzed variables were tested for normality of distribution
by the Shapiro-Wilk test. Normally distributed variables
were compared by the t test and non-normally distrib-
uted ones by the Mann-Whitney test between the COPD
and non-COPD group, or between the surgery and the
non-surgery group. Comparisons between the percent-
ages of patients with each GOLD grade or tumor type
were made using the χ2 test or with Fisher’s exact test.
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ing surgery in the above-mentioned univariate analyses
were entered into a forward-and-backward stepwise lo-
gistic regression analysis to identify independent factors
for the relinquishment of surgery. Statistical analyses
were performed with PASW Statistics version 18.0 (SPSS
Inc, Chicago, IL), and a P value of less than 0.05 was
considered statistically significant.
Results
Demographic distribution of patient characteristics
among the study population
Data from 320 patients with lung cancer who were se-
quentially registered and underwent bronchoscopy from
August 2010 to July 2012 were obtained from hospital
records (Figure 1). Fifty patients who had not undergone
pulmonary assessment by spirometry were subsequently
excluded from the study population. In total, 234 pa-
tients with lung cancers underwent spirometry screening
assessment at bronchoscopy. A further 36 patients with
lung cancers did not undergo spirometry at bronchos-
copy but received it at thoracic surgery or before bron-
choscopy. Ultimately, the study population included 270
patients who underwent spirometry and bronchoscopy
among 320 patients with lung cancer (84.4%) (Figure 1).
In the present population, 54.4% of the patients who
underwent bronchoscopy had COPD (147/270 cases).
Table 1 shows a comparison of the patient characteris-
tics among the study groups. Only 8.5% of the total
study population had been managed as COPD. Overall,
the 147 patients in the COPD group were older and
more likely to be male, and to have a more extensive
smoking history, as compared with the 123 patients inFigure 1 Study profile. Schematic diagram showing the study profile.the non-COPD group. When we evaluated the severity
of airflow obstruction in the COPD group, the incidence
of GOLD grade 1 and 2 was significantly higher than
that of GOLD grade 3 (Figure 2 and Table 2). We also
evaluated chest CT findings to determine the involvement
of emphysema. The percentage of the COPD group with
involvement of emphysema in the chest CT findings was
almost twice as high as that of the non-COPD group
(38.8% vs 20.3%, respectively).
Association of COPD prevalence with lung cancer
characteristics in Japanese patients undergoing
bronchoscopy
To evaluate the association of COPD with characteristics
of lung cancer, the pathological findings, EGFR mutation
status, clinical staging, and decision for thoracic surgery
were compared between the COPD group and the non-
COPD group (Table 3).
Regarding pathologic findings, the incidence of adeno-
carcinoma was significantly lower in the COPD group
than in the non-COPD group. In the present study,
EGFR mutation was observed only in the patients with
adenocarcinoma (40/145 cases; 27.6%). In contrast, the
number of cases in which EGFR mutation status was not
determined was significantly higher in the COPD group
than in the non-COPD group. Although determination
of the clinical stage should be essential in order to
propose the therapeutic options for lung cancer, some
cases in which clinical staging had not been completed
were observed in the study population. The number of
these cases was significantly higher in the COPD group
than in the non-COPD group. In contrast, the proportion
of patients with each classification in the clinical staging
Table 1 Patient characteristics among non-COPD and COPD patients
All cases (n = 270) Non-COPD (n = 123) COPD (n = 147) p value
Cases 100 (270) 45.6 (123) 54.4 (147) 0.0001#
Age, yearsa 70.1 (39–88) 67.9 (39–82) 71.9 (51–87) 0.0001#
Sex, male 73.7 (199) 62.6 (77) 83.0 (122) 0.0001#
History of smoking 78.9 (213) 65.9 (81) 89.8 (132) 0.0001#
COPD managedb 8.5 (23) 1.6 (2) 14.3 (21) 0.0001#
COPD-related systemic comorbidities 55.9 (151) 52.8 (65) 58.5 (86) 0.390
Diabetes 19.3 (52) 16.3 (20) 21.8 (32) 0.280
Ischemic cardiac disease 7.4 (20) 2.4 (3) 11.6 (17) 0.004#
Hypertension 38.1 (103) 37.4 (46) 38.8 (57) 0.900
Hyperlipidemia 11.9 (32) 8.1 (10) 15.0 (22) 0.092
n indicates number.
aData are shown as mean (range).
bindicates the patients who had been diagnosed as COPD before bronchoscopy.
All other data are shown as% (numbers).
#p < 0.05.
COPD: chronic obstructive pulmonary disease.
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which the clinical staging was not determined. Among the
total study population, the number of thoracic surgeries
performed was significantly lower in the COPD group than
in the non-COPD group.
Critical impact of the severity of airflow obstruction on the
decision to propose thoracic surgery with curative intent
To explore whether or not the severity of airflow ob-
struction might affect the decision to propose thoracicFigure 2 Population of non-COPD and COPD in Japanese patients wit
COPD (n = 123) and COPD (n = 147) among Japanese patients with lung ca
1 (n = 95), grade 2 (n = 41), grade 3 (n = 11), and grade 4 (n = 0).surgery with curative intent, patients at stage 3B and 4
were excluded from the analysis because they were not
eligible for thoracic surgery. In addition, patients for
whom the clinical staging had not been completed were
also excluded. As a result, we evaluated data from 185
patients with lung cancer at stage 1A to 3A who under-
went spirometry and bronchoscopy. These patients were
subdivided into those who underwent thoracic surgery
(135 cases) and those who did not (50 cases). The char-
acteristics and spirometric data for the patients with orh lung cancer. Schematic presentation of the percentage of non-
ncer. Patients with COPD were classified by GOLD grade, that is, grade
Table 2 Physical assessment variables among non-COPD and COPD patients
All cases (n = 270) Non-COPD (n = 123) COPD (n = 147) p value
BMI (kg/m2)a 22.1 (2.8) 22.0 (2.8) 22.2 (2.9) 0.749
spirometric variables
%VCa 105.9 (20.6) 104.8 (20.8) 106.7 (20.5) 0.520
FEV1 (ml)a 2062 (610) 2302 (555) 1861 (583) 0.0001#
FEV1/FVCa 67.3 (12.6) 77.8 (6.3) 58.9 (10.3) 0.0001#
%FEV1 predicteda 98.2 (25.7) 109.4 (21.1) 88.9 (25.4) 0.0001#
%ICa 85.9 (19.5) 83.6 (17.8) 87.9 (20.6) 0.111
chest CT finding
emphysema 30.4 (82) 20.3 (25) 38.8 (57) 0.001#
n indicates number.
aData are shown as mean (SD).
All other data are shown as% (numbers).
#p < 0.05.
BMI: body mass index; VC: vital capacity; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; IC: inspiratory capacity; GOLD: the Global Initiative
for Chronic Obstructive Lung Disease.
Table 3 Characteristics of lung cancer status among









Adenocarcinoma 53.7 (145) 69.9 (86) 40.1 (59)##
Sq 27.0 (73) 17.9 (22) 34.7 (52)##
NSCLC 10.4 (28) 4.9 (6) 15.0 (21)##
SCLC 6.7 (18) 5.7 (7) 7.5 (11)
Large 2.2 (6) 1.6 (2) 2.7 (4)
Clinical stage 0.046#
1A 25.6 (69) 30.8 (38) 21.1 (31)
1B 13.7 (37) 13.0 (16) 13.6 (20)
2A 9.6 (26) 13.0 (16) 7.5 (11)
2B 7.8 (21) 9.8 (12) 6.1 (9)
3A 11.9 (32) 8.9 (11) 14.3 (21)
3B 5.6 (15) 4.1 (5) 6.8 (10)
4 17.0 (46) 16.3 (20) 17.7 (26)
ND 8.9 (24) 4.1 (5) 12.9 (19)##
Thoracic surgery 0.0001#




Yes 14.8 (40) 21.1 (26) 9.5 (14)##
No 55.2 (149) 59.3 (73) 51.7 (76)
ND 30.0 (81) 19.5 (24) 38.8 (57)##
n indicates number.
All data are shown as% (numbers).
ND indicates “not determined”.
#p < 0.05.
##indicates a significant difference compared with the non-COPD group.
COPD: chronic obstructive pulmonary disease; Sq: squamous cell carcinoma;
NSCLC: non-small cell lung carcinoma; SCLC: small cell lung carcinoma; Large:
large cell carcinoma; EGFR: epidermal growth factor receptor.
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and 5. The characteristics of lung cancer among these
groups are also shown in Table 6. Univariate analysis
identified a significantly lower frequency of thoracic
surgery among the patients of greater age and with
more severe airway obstruction, and advanced clinical
staging. Univariate analysis also identified a significantly
higher frequency of thoracic surgery among patients with
adenocarcinoma. Finally, all of the factors with a signifi-
cant association in the univariate analysis were applied to
the multivariate model to identify variables independ-
ently associated with the decision for thoracic surgery.
Multivariate analysis identified more severe airway ob-
struction, advanced clinical stagings, and higher age, as
independent factors affecting the decision on thoracic
surgery (Table 7).
Discussion
This is the first study to evaluate the clinical impact of
the prevalence and severity of COPD on a large cohort
of Japanese patients with lung cancer who underwent
bronchoscopy. Mounting evidence suggests that there
is a close association between COPD and lung cancer
[9,10,13]. For example, a case-control study by Young,
et al. demonstrated a high prevalence of COPD in pa-
tients with newly diagnosed lung cancer [10]; however,
their study population comprised only Caucasian an-
cestry, and nonsmokers with lung cancer were also
excluded [10]. Although many lines of evidence suggest
that EGFR mutations are more common among women,
never-smokers, patients with adenocarcinoma-type lung
cancer, and patients of East Asian ethnicity including
Japanese [11,19], the association of COPD prevalence with
EGFR mutations has not been fully evaluated. Indeed,
21.1% of our Japanese study population was non-smokers,
Table 4 Patient characteristics in the thoracic surgery and non-thoracic surgery groups
All cases (n = 185) Non-surgery (n = 50) Surgery (n = 135) p value
Cases 100 (185) 27.0 (50) 73.0 (135) 0.0001#
Age, yearsa 70.3 (39–88) 74.6 (62–80) 68.7 (39–86) 0.0001#
Sex, male 72.4 (134) 76.0 (38) 71.1 (96) 0.581
History of smoking 78.9 (213) 82.0 (41) 77.0 (104) 0.549
COPD diagnosedb 49.7 (92) 66.0 (33) 43.7 (59) 0.012#
COPD managedc 9.2 (17) 20.0 (10) 5.2 (7) 0.004#
COPD-related systemic comorbidities 57.3 (106) 60.0 (30) 56.3 (76) 0.739
Diabetes 20.0 (37) 30.0 (15) 16.3 (22) 0.061
Ischemic disease 7.6 (14) 10.0 (5) 6.7 (9) 0.532
Hypertension 40.5 (75) 40.0 (20) 40.7 (55) 1.000
Hyperlipidemia 11.4 (21) 10.0 (5) 11.8 (16) 0.799
n indicates number.
aData are shown as mean (range).
bindicates the patients who were firstly diagnosed as COPD at bronchoscopy.
cindicates the patients who had been diagnosed as COPD before bronchoscopy.
All other data are shown as% (numbers).
#p < 0.05.
COPD: chronic obstructive pulmonary disease.
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Compatible with the distribution of pathological findings,
there was significantly higher rate of EGFR mutation in the
non-COPD group than in the COPD group (Table 3). Al-
though a recent study by Loganathan, et al. also showed
that 67% of 436 patients with newly diagnosed lung cancerTable 5 Physical assessment variables among patients having
All cases (n = 185) N
BMI (kg/m2)a 22.2 (3.0)
Spirometric variables
%VCa 108.8 (20.6)
FEV1 (ml)a 2126 (612)
FEV1/FVCa 67.6 (13.0)




GOLD grade 1 34.6 (64)
GOLD grade 2 10.8 (20)
GOLD grade 3 4.3 (8)




aData are shown as mean (SD).
All other data are shown as% (numbers).
#p < 0.05.
##indicates a significant difference compared with the non-surgery group.
BMI: body mass index; VC: vital capacity; FEV1: forced expiratory volume in 1 secon
for Chronic Obstructive Lung Disease.had undergone spirometry prior to receiving treatment [9],
our study analyzed the prevalence of COPD and its severity
in 84.4% of patients with newly diagnosed lung cancer,
mainly by performing spirometry at bronchoscopy. Fur-
thermore, almost 50% of Loganathan, et al.’s population
were women [9], whereas only 26.7% of our populationthoracic surgery and non-thoracic surgery
on-surgery (n = 50) Surgery (n = 135) p value
22.3 (2.4) 22.1 (3.2) 0.760
104.5 (20.4) 110.4 (19.6) 0.031
1810 (591) 2242 (580) 0.0001#
62.7 (17.0) 69.5 (10.7) 0.01#
93.7 (28.7) 104.3 (23.7) 0.020#
85.3 (19.7) 88.7 (18.6) 0.314
0.002#
34.0 (17) 56.3 (76)##
44.0 (22) 31.1 (42)
10.0 (5) 11.1 (15)
12.0 (6) 1.5 (2)##
0 (0) 0 (0)
36.0 (18) 28.9 (39) 0.374
d; FVC: forced vital capacity; IC: inspiratory capacity; GOLD: the Global Initiative
Table 6 Characteristics of lung cancer among patients











Adenocarcinoma 58.4 (108) 44.0 (22) 63.7 (86)##
Sq 30.8 (57) 38.0 (19) 28.1 (38)
NSCLC 5.4 (10) 10.0 (5) 7.4 (10)
SCLC 3.2 (6) 8.0 (4) 1.5 (2)##
Large 2.2 (4) 0 (0) 3.0 (4)
Clinical stage 0.0001#
1A 37.3 (69) 26.0 (13) 41.5 (56)
1B 19.4 (36) 14.0 (7) 21.5 (29)
2A 14.6 (27) 10.0 (5) 16.3(22)
2B 11.4 (21) 8.0 (4) 12.6 (17)
3A 17.3 (32) 42.0 (21) 8.1 (11)##
EGFR status 0.0001#
Yes 16.2 (30) 8.0 (4) 19.3 (26)
No 61.6 (114) 28.0 (14) 74.1 (100)##
ND 22.2 (41) 64.0 (32) 6.7 (9)##
n indicates number.
aData are shown as mean (range). bData are shown as mean (SD).
All other data are shown as% (numbers).
ND indicates “not determined”.
#p < 0.05.
##indicates a significant difference compared with the non-surgery group.
Sq: squamous cell carcinoma; NSCLC: non-small cell lung carcinoma; SCLC:
small cell lung carcinoma; Large: large cell carcinoma; EGFR: epidermal growth
factor receptor.
Table 7 Multivariate analysis of independent factors in
decision-making process for proposing thoracic surgery
with curative intent
Variables Odds ratio 95% CI p value











Stage 1A versus stage 1B 1.084 0.326–3.602 0.895
Stage 1A versus stage 2A 0.679 0.185–2.491 0.559
Stage 1A versus stage 2B 0.705 0.172–2.895 0.628
Stage 1A versus stage 3A 0.062 0.019–0.202 <0.0001#
Age (per one year) 0.858 0.802–0.917 <0.0001#
#p < 0.05.
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and the United States of America might support the differ-
ent proportion of women patients with lung cancer be-
tween our study and their studies [20,21]. Although we
previously demonstrated that 43.2% of the patients under-
going major lung resection had COPD (178/412 cases)
[14], here the prevalence of COPD was found to be 54.4%
in Japanese patients with lung cancer who underwent
bronchoscopy. In the present population, 61.3% of men
had COPD (122/199 cases), whereas only 35.2% of women
had COPD (25/71 cases). In addition, 95.5% of men had a
history of smoking in our population, whereas 67.6% of
women were non-smokers. In contrast, the percentage of
non-smokers among women with lung cancer was only
10.5% in the study of Loganathan et al. Thus, the lower
prevalence of COPD in women with lung cancer might be
explained by the high rate of non-smokers among women
in our Japanese population [13,22]. Although de Torres,
et al. demonstrated, by using a well-characterized cohort of
patients with COPD, that the incidence of dense lung can-
cers decreased as the severity of the airflow obstruction at
baseline increased [23], the severity of COPD in Japanese
patients with newly diagnosed lung cancer was classified
mainly as GOLD grade 1 and 2 rather than as GOLD grade
3. Furthermore, our data showed that most patients were
newly classified with COPD (84.4%; 124/147 cases), com-
patible with the incidence of the severity of COPD shown
above or previously [13,23]. It should be noted that in
comparing patients undergoing thoracic surgery, COPD
patients had an average postoperative stay that was 61%
higher, and a 100% greater need of prolonged oxygen ther-
apy, than patients without COPD, indicating the clinical
impact of the coexistence of COPD [14].
The prevalence of COPD might increase in Japanese
patients with lung cancer, whereas the impact of COPD-
related systemic comorbidities is also increasingly recog-
nized in clinical aspects of COPD [7]. Thus, whether or
not the decision-making process involved in proposing
the therapeutic management of lung cancer might be
independently affected by COPD in patients with lung
cancer remains elusive. To address this issue, we evalu-
ated whether or not completion of clinical staging and
proposal of thoracic surgery with curative intent might
be affected by the coexistence of COPD. The percentage
of patients in whom clinical staging had been not com-
pleted was significantly higher in the COPD group than in
the non-COPD group. More than half of these patients
were referred to other hospitals for further support, while
the others were patients with disease recurrence. The pro-
portion of patients with each classification in the clinical
staging was compatible with that reported in previous
studies about thoracic surgery [24]. Clinical guidelines rec-
ommend the assessment of spirometry to evaluate the
optimum selection of surgical procedure in view of the
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Therefore, we analyzed data from 185 patients with lung
cancer at stage 1A to 3A because these patients are gener-
ally eligible for thoracic surgery with curative intent
[17,26]. Even among these surgical candidates, however,
the number of surgeries performed was significantly lower
in the COPD group (64.1%; 59/92 cases) than in the non-
COPD group (81.7%; 76/93 cases) (Table 4). Furthermore,
our data showing that COPD-related systemic comor-
bidities might not be independent factors for proposing
thoracic surgery with curative intent was supported by
previous data as described above [14]. Thus, these data
indicate that the decision-making process for the thera-
peutic management of Japanese lung cancer patients
might be affected by the prevalence and severity of COPD.
Finally, we evaluated whether or not the severity of COPD,
classified by GOLD grade, might be an independent factor
affecting the proposal of thoracic surgery with curative in-
tent. Multivariate analysis indicated that severity of COPD
was a critical and independent factor for proposing thor-
acic surgery with curative intent to Japanese patients with
lung cancer who underwent bronchoscopy. This finding
might be supported by our previous study showing that in
comparing patients undergoing thoracic surgery, COPD
patients with an FEV1/FVC below 0.70 had an average
postoperative stay that was 61% higher, and a 100% greater
need of prolonged oxygen therapy (POT), than patients
without COPD [14].
Some limitations of the present study deserve men-
tion. First, the reversibility test was performed in only
62.2% of patients (168/270 cases), although COPD was
defined as a postpronchodilator FEV1/FVC below 0.7
[16]. This limitation is present in other studies that have
evaluated the prevalence of COPD [9,10,27]. The other
explanation might be the preoperative pulmonary assess-
ment based on the clinical guidelines, in which the need
to perform a reversibility test for assessment of airflow
obstruction is not mentioned [8,25]. Although a recent
study suggests that some COPD patients show relatively
high reversibility for a short-acting beta2-agonist [28],
only 1.2% of 168 cases showed significant reversibility in
the present study, indicating that Japanese patients with
both lung cancer and COPD might have different char-
acteristics from that population [27]. Second, the present
study retrospectively analyzed 270 out of a total of 320
cases with lung cancer in a single institution and there-
fore might be subject to selection bias. However, analyz-
ing the data from 84.4% of all patients in a single
institution who were sequentially registered and underwent
bronchoscopy from 2010 to 2012 might minimize the pos-
sible contribution of the selection bias for patients with
lung cancer.
Although many studies suggest that COPD remains
underdiagnosed in the patients with lung cancer [13,14],Zang, et al. suggest that awareness of COPD might con-
tribute the conformity to GOLD treatment guideline for
stable condition and acute exacerbation of COPD in
lung cancer patients during hospitalization [13]. When
spirometry was performed at bronchoscopy, the median
time from the date of spirometry to thoracic surgery was
50 days in the present study. Therefore, comprehensive
assessment of COPD at bronchoscopy might allow us to
implement the optimum management for lung cancer
patients [29,30].
Conclusions
In the present study, the high prevalence of COPD among
Japanese patients with newly diagnosed lung cancer was
shown. Although further investigation into the validity of
the assessment of COPD at bronchoscopy from studies of
patients with lung cancer from other institutions is war-
ranted, we conclude that appropriate risk stratification and
comprehensive management of patients with lung cancer
and COPD might be made by assessment of the coexist-
ence and severity of COPD at the time of bronchoscopy.
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